CureDuchenne Blog

Update on Phase 3 Tadalafil Trial

We are sharing the following information from Lilly on their Phase 3 Tadalafil Trial   We are writing to share disappointing news about our Phase 3 study of tadalafil in […]

BioMarin DMD Update for Patient Groups

  We wanted to share the following information from BioMarin in regards to yesterday’s news on the FDA decision on Kyndrisa (drisapersen).     Dear Patient Group Representative, As you […]

CureDuchenne-Funded Trial for Cardiac Therapy

  Capricor Therapeutics is actively recruiting participants for a clinical trial for a potential cardiac cell therapy for those with Duchenne muscular dystrophy.  CureDuchenne funded Capricor to support this trial […]

FDA Advisory Committee Meeting

  We are looking forward to the U.S. Food & Drug Administration (FDA) Advisory Committee meeting on  Tuesday, November 24. This will be an important day for the Duchenne community. […]

You are Pioneers Once Again

  We are pleased to share the following letter from the CEO of PTC Therapeutics to the Duchenne community.  CureDuchenne funded PTC Therapeutics back in 2003 and we are proud […]